Many patients with advanced CKD will develop anemia and impaired iron homeostasis, which are associated with adverse outcomes. Analyses have demonstrated that IV iron reduces the risk for myocardial infarction, stroke, and heart failure hospitalization in patients with CKD on dialysis, particularly at high doses. In addition, multiple studies have demonstrated that IV iron has resulted in a reduction of ESA dose.
Although IV iron administration is associated with an increased risk for infection and hypersensitivity reactions, it is the most effective method for increasing hemoglobin, ferritin, and transferrin saturation (TSAT), and reducing ESA use and blood transfusions.
Learn more about CKD anemia management.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pradeep Arora. Fast Five Quiz: Management of Chronic Kidney Disease Anemia - Medscape - Apr 19, 2022.